Study #2019-0540
A Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 with Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
MRx0518
Description
This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Cancer
Study phase:
Phase I
Physician name:
Cullen Taniguchi
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.